retatrutide phase 2 obesity trial results just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a study: • Up to 24.2% mean weight loss at 48 weeks Acute and chronic effects of

Evidence for continued use The degree of benefit reported in the study is very close to that seen in a different trial, called the SELECT study, which looked at the reduction in heart events in people taking semaglutide for obesity

Begin your GLP-1 and Hormonal Health Chicago journey today with a free virtual consultation with a doctor to see if Wegovy or Zepbound is right for you

Or work with me directly to sort out whether your symptoms are from the B12, from MCAS, or from something else

Most patients report noticeable improvements in libido and arousal with the first few doses

Anti-inflammatory signaling

In practice, this often means prioritizing: Fish